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Letter to the Editor
The role of B cells in acute graft- 
versus-host disease
TO THE EDITOR: Mounting evidences implicates B cells 
in the pathogenesis of chronic graft-versus-host disease 
(GVHD). The body of evidence includes findings such as 
correlation between chronic GVHD and antibody pro-
duction against Y chromosome-encoded minor histo-
compatabilty antigens (mHA) generated after sex-mis-
matched allogeneic stem cell transplantation (SCT), the clin-
ical response of steroid-refractory chronic GVHD to ritux-
imab, and association between high serum B cell-activating 
factor (BAFF) levels and chronic GVHD [1]. However, the 
role of B cells in acute GVHD remains controversial. Some 
studies that showed the association of high B cell count 
in the grafts in SCT patients with acute GVHD and beneficial 
effects of rituximab (used for B cell lymphoma treatment 
before transplantation) in acute GVHD patients, have sug-
gested the possible role of B cells in the development of 
acute GVHD.
Kim et al. reported that the BAFF level/absolute lympho-
cyte count (ALC) ratio or that of APRIL (a proliferation-in-
ducing ligand) level/ALC at the time of acute GVHD diag-
nosis was associated with disease severity [2]. In their study, 
patients with grade III-IV acute GVHD (6) had higher BAFF 
level/ALC or APRIL level/ALC ratio than the corresponding 
ratio observed in patients with grade II acute GVHD (9). 
These findings suggest that BAFF level/ALC or APRIL lev-
el/ALC ratio can help determine the severity of acute GVHD 
and need to be confirmed in large prospective studies. 
However, it would be somewhat unreasonable to conclude 
that B cells may play an important role in the development 
of acute GVHD on the basis of these findings alone. First, 
counting the number of B cells should be performed along 
with measurement of the BAFF or APRIL levels because 
higher serum BAFF levels may reflect relative B lymphope-
nia depending on the period after transplantation. 
Furthermore, comparison of the findings for patients with 
and without acute GVHD for the same period after alloge-
neic SCT is essential for investigating the relationship be-
tween B cells and acute GVHD. 
BAFF has a complex, dichotomous role in immunity, 
which is mediated by the differential regulation of T cell- 
and B cell-dependent immune responses [3]. BAFF, a critical 
regulator of normal B cell homeostasis in mice and humans, 
also promotes T cell activation and survival [4]; these T 
cells play a pivotal role in acute GVHD pathogenesis. 
However, recent studies have also demonstrated the neg-
ative regulatory role of BAFF in T cell function [3, 5]. 
Walters et al. found that BAFF-transgenic mice accepted 
islet allografts and showed delayed rejection of skin 
allografts. On the basis of these results, they proposed that 
BAFF plays an anti-inflammatory role in T cell biology 
by promoting the expansion of regulatory T cells [3]. We 
studied the potential protective effect of BAFF against acute 
GVHD during the peritransplantation period in the setting 
of allogeneic SCT in humans [5]. Thus, further experimental 
and clinical studies are needed to elucidate the role of B 
cells in the development of acute GVHD and gain more 
insight into the pathogenesis of acute GVHD by studying 
the association of BAFF with B cells and T cells.
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